Edwards Lifesciences (NYSE:EW) Price Target Raised to $100.00

Edwards Lifesciences (NYSE:EW) had its price objective lifted by Royal Bank Of Canada from $95.00 to $100.00 in a research report sent to investors on Friday morning, MarketBeat reports. Royal Bank Of Canada currently has an outperform rating on the medical research company’s stock.

A number of other brokerages also recently issued reports on EW. JPMorgan Chase & Co. boosted their price objective on shares of Edwards Lifesciences from $85.00 to $90.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Jefferies Financial Group set a $98.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a research report on Wednesday, October 29th. National Bankshares set a $92.00 price target on Edwards Lifesciences in a research report on Friday, October 31st. Stifel Nicolaus set a $100.00 price objective on Edwards Lifesciences and gave the company a “buy” rating in a research report on Friday. Finally, Wall Street Zen downgraded Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $92.91.

Edwards Lifesciences Price Performance

NYSE EW opened at $86.26 on Friday. The company has a 50-day moving average price of $80.95 and a 200-day moving average price of $78.76. Edwards Lifesciences has a 52 week low of $65.94 and a 52 week high of $87.89. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $50.05 billion, a P/E ratio of 37.18, a PEG ratio of 3.82 and a beta of 0.97.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The company had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the firm posted $0.67 earnings per share. The firm’s revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Equities research analysts anticipate that Edwards Lifesciences will post 2.45 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,314,725.84. This trade represents a 24.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the sale, the vice president owned 22,002 shares in the company, valued at approximately $1,816,265.10. The trade was a 4.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.34% of the company’s stock.

Institutional Trading of Edwards Lifesciences

A number of institutional investors have recently bought and sold shares of the stock. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth about $25,000. Quantbot Technologies LP bought a new stake in Edwards Lifesciences in the first quarter worth about $26,000. SouthState Corp purchased a new position in shares of Edwards Lifesciences during the first quarter valued at approximately $27,000. Rosenberg Matthew Hamilton bought a new position in shares of Edwards Lifesciences during the second quarter valued at approximately $28,000. Finally, True Wealth Design LLC raised its holdings in shares of Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock worth $28,000 after buying an additional 259 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.